NRx Pharmaceuticals, Inc. (NRXP) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
NRx Pharmaceuticals, Inc. (NRXP) Earnings Overview
As of June 23, 2026, NRx Pharmaceuticals, Inc. (NRXP) reported trailing twelve-month net income of -$25M, reflecting +43.9% year-over-year growth. The company earned $-0.76 per diluted share over the past four quarters, with a net profit margin of -2336.5%.
Looking at the long-term picture, NRXP's historical earnings data spans multiple years. The company achieved its highest annual net income of $408,427 in fiscal 2019.
NRx Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AXSM (-$188M net income, -28.7% margin), ALTO ($29M net income, 1.5% margin), INMB (-$42M net income, -91866.0% margin), NRXP has room to improve margins relative to the peer group. Compare NRXP vs AXSM →
NRXP Earnings vs Peers
Earnings metrics vs comparable public companies
NRXP Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$29M | -13.9% | -$16M | $-1.34 | -2336.5% | -1324.4% |
| 2024 | -$25M | +16.7% | -$20M | $-2.39 | - | - |
| 2023 | -$30M | +24.2% | -$28M | $-3.98 | - | - |
| 2022 | -$40M | +57.3% | -$44M | $-0.60 | - | - |
| 2021 | -$93M | -79.7% | -$95M | $-7.44 | - | - |
| 2020 | -$52M | -12777.2% | -$22M | $-1.51 | - | - |
| 2019 | $408,427 | +517.9% | $-713,187 | $0.80 | - | - |
| 2018 | $66,101 | +163.0% | -$1M | $0.07 | - | - |
| 2017 | $-105,000 | - | $0 | $-0.12 | - | - |
Download Data
Export NRXP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NRXP — Frequently Asked Questions
Quick answers to the most common questions about buying NRXP stock.
What is NRXP earnings per share (EPS)?
NRXP trailing twelve-month (TTM) diluted EPS is $-0.76, reflecting +43.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is NRx Pharmaceuticals, Inc.'s net income?
NRx Pharmaceuticals, Inc. (NRXP) trailing twelve-month net income is $-25M as of 2025. Earnings grew +43.9% year-over-year.
Is NRXP profitable?
NRXP is not currently profitable on a TTM basis, reporting a net loss of $-25M. Net margin is -2336.5%. Investors should monitor for a return to profitability.
What is NRXP's earnings growth rate?
NRXP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are NRXP's profit margins?
NRx Pharmaceuticals, Inc. net profit margin is -2336.5%, operating margin is -1324.4%, and gross margin is +58.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is NRXP growing earnings?
Yes, NRXP earnings are accelerating — EPS growth of +43.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-25M. Earnings momentum is strengthening.
What was NRXP's best earnings year?
NRx Pharmaceuticals, Inc.'s highest annual net income on record is $408427.00, achieved in fiscal year 2019. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were NRXP's earnings last quarter?
NRXP's most recent reported quarter was Q1 2026. Net income was $-1M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.